Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.

Autor:	Atsou S; Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le KremLin-Bicêtre, France., Schellenberg C; Université de Lorraine, INSERM, Défaillance Cardiovasculaire Aigüe et Chronique DCAC U1116, 54505 Vandoeuvre-les-Nancy, France., Lagrange J; Université de Lorraine, INSERM, Défaillance Cardiovasculaire Aigüe et Chronique DCAC U1116, 54505 Vandoeuvre-les-Nancy, France., Lacolley P; Université de Lorraine, INSERM, Défaillance Cardiovasculaire Aigüe et Chronique DCAC U1116, 54505 Vandoeuvre-les-Nancy, France., Lenting PJ; Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le KremLin-Bicêtre, France. Electronic address: peter.lenting@inserm.fr., Denis CV; Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le KremLin-Bicêtre, France. Electronic address: https://twitter.com/InsermU1176., Christophe OD; Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le KremLin-Bicêtre, France., Regnault V; Université de Lorraine, INSERM, Défaillance Cardiovasculaire Aigüe et Chronique DCAC U1116, 54505 Vandoeuvre-les-Nancy, France.
Jazyk:	angličtina
Zdroj:	Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Jan; Vol. 22 (1), pp. 112-125. Date of Electronic Publication: 2023 Sep 29.
DOI:	10.1016/j.jtha.2023.09.017
Abstrakt:	Background: The effect of factor VIII (FVIII) or emicizumab on thrombin generation is usually assessed in assays using synthetic phospholipids. Here, we assessed thrombin generation at the surface of human arterial cells (aortic endothelial cells [hAECs] and aortic vascular smooth muscle cells [hVSMCs]). Objectives: To explore the capacity of hAECs (resting or stimulated) and hVSMCs to support thrombin generation by FVIII or emicizumab. Methods: Primary hVSMCs and hAECs were analyzed for tissue factor (TF)-activity and antigen, phosphatidylserine (PS)-exposure, tissue factor pathway inhibitor (TFPI)-content and thrombomodulin expression. Cells were incubated with FVIII-deficient plasma spiked with FVIII, emicizumab, activated prothrombin complex concentrate (APCC) or combinations thereof. Results: TF activity and PS-exposure were present on both hVSMCs and hAECs. In contrast, thrombomodulin and TFPI were expressed on hAECs, while virtually lacking on hVSMCs, confirming the procoagulant nature of hVSMCs. Tumor necrosis factor α-mediated stimulation of hAECs increased not only TF antigen, TF activity, and PS-exposure but also TFPI and thrombomodulin expression. As expected, FVIII and emicizumab promoted thrombin generation on nonstimulated hAECs and hVSMCs, with more thrombin being generated on hVSMCs. Unexpectedly, FVIII and emicizumab increased thrombin generation to a lesser extent on stimulated hAECs compared with nonstimulated hAECs. Finally, adding emicizumab to FVIII did not further increase thrombin generation, whereas the addition of emicizumab to APCC resulted in exaggerated thrombin generation. Conclusion: Tumor necrosis factor stimulation of hAECs increases both pro- and anticoagulant activity. Unexpectedly, the increased anticoagulant activity is sufficient to limit both FVIII- and emicizumab-induced thrombin generation. This protective effect disappears when emicizumab is combined with APCC. Competing Interests: Declaration of competing interests P.J.L. receives research funding to the institute from Hoffman-Laroche Ltd, Institut Roche, Pfizer, Sanofi, and Sobi. The other authors declare no conflict of interest. (Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu